论文信息 - Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup - 字舞流文

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup

U. Germing | A. Giagounidis | C. Strupp | C. Aul | B. Hildebrandt | M. Heinsch | Aristoteles Giagounidis | U. Germing

[1] M. Gordon. Efficacy of Lenalidomide in Myelodysplastic Syndromes , 2006 .

[2] A. Ganser,et al. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31–q33 with a combination of all-trans-retinoic acid and tocopherol-α: a phase II study , 2005, Annals of Hematology.

[3] Angus G. Dalgleish,et al. The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[4] U. Germing,et al. The 5q- syndrome. , 2008, Cancer treatment and research.

[5] C. Schoch,et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.

[6] U. Germing,et al. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome , 2003, Leukemia.

[7] J. Wainscoat,et al. The 5 q-Syndrome , 2002 .

[8] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[9] S. Asano,et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. , 1993, Leukemia.

[10] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.